Patients On Pfizer’s initiative to return clinical trial data to pati... Among the most common reasons for dropping out, patients cite a lack of communication about the trial
R&D Focus on the positive to stop public perception being a barr... Public misconceptions surrounding the process, its risks and its benefits remain a significant barrier to clinical trial participation, which is not surprising in a world where the only int
News Agios shares slide as it abandons sickle cell candidate Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
